Skip to main content
3D Medicines Inc. logo

3D Medicines Inc. — Investor Relations & Filings

Ticker · 1244 ISIN · KYG8872R1011 HKEX Manufacturing
Open in API
Filings indexed 145 across all filing types
Latest filing 2022-12-13 Governance Information
Country HK Hong Kong
Listing HKEX 1244

About 3D Medicines Inc.

https://www.3d-medicines.com

3D Medicines Inc. is an oncology-focused, commercial-stage biopharmaceutical company specializing in the development and commercialization of next-generation immuno-oncology therapies. The company leverages global research and development capabilities and internal discovery platforms to advance a pipeline of innovative drug candidates. Its core mission is to address unmet medical needs in cancer treatment, aiming to transform cancer into a chronic disease and provide substantial value to patients and healthcare providers globally.

Recent filings

Filing Released Lang Actions
Amended and Restated Memorandum of Association
Governance Information Classification · 95% confidence The document is titled 'Amended and Restated Memorandum of Association' and 'Amended and Restated Articles of Association' of 3D Medicines Inc., adopted pursuant to a special resolution related to the company's listing on the Hong Kong Stock Exchange. It contains detailed corporate governance provisions, definitions, share capital structure, and procedural rules for the company. There is no financial data, earnings information, or audit results presented. The content is focused on the company's internal rules, board structure, shareholder rights, and governance framework. This matches the description of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is substantial (15,000 characters), indicating it is the actual governance document, not just an announcement. Therefore, the appropriate classification is CGR with high confidence.
2022-12-13 English
Announcement of Offer Price and Allotment Results
Share Issue/Capital Change Classification · 95% confidence The document is an 'Allotment Results' announcement from the Hong Kong Stock Exchange (HKEX) for 3D Medicines Inc. It provides links to various PDF files detailing the results of share applications, successful applicants, and share certificate collection. This is a standard regulatory announcement regarding the outcome of an Initial Public Offering (IPO) or share issuance process. Since it is a regulatory announcement regarding the issuance of shares and the results of the allotment process, it fits best under the 'Share Issue/Capital Change' category.
2022-12-13 English
Documents on Display
Regulatory Filings Classification · 95% confidence The document is a placeholder message from the Hong Kong Exchanges and Clearing Limited stating that the requested document has been removed by the issuer. Since it does not contain any substantive financial or corporate information and serves as a system-generated notice regarding a missing filing, it falls under the general regulatory announcement category.
2022-11-28 English
GREEN APPLICATION FORM
Capital/Financing Update Classification · 95% confidence The document is an application form for a Hong Kong public offering of shares by 3D Medicines Inc., including detailed terms about the global offering, allocation, and legal disclaimers. It references the prospectus dated November 29, 2022, and contains no financial statements or management discussion. It is clearly related to the capital raising process and share issuance. Therefore, this document is best classified as a Capital/Financing Update (CAP) since it pertains to the offering and issuance of new shares to the public.
2022-11-28 English
GLOBAL OFFERING
Capital/Financing Update Classification · 100% confidence The document is a prospectus for a global offering of shares by 3D Medicines Inc., including detailed information about the number of shares offered, offer price, application procedures, timetable for the offering, and regulatory disclaimers. It is clearly an offering document related to an initial public offering (IPO) or share issuance. This type of document is not an annual report, earnings release, or management report, but rather a detailed capital raising document. According to the filing definitions, updates on company fundraising or capital structure changes fall under Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains substantive details about the offering, not just an announcement or a brief summary. Therefore, the correct classification is Capital/Financing Update (CAP).
2022-11-28 English
GLOBAL OFFERING
Capital/Financing Update Classification · 95% confidence The document is an announcement related to a Global Offering by 3D Medicines Inc., detailing the number of shares offered, pricing, application procedures, and the expected timetable for the offering. It includes disclaimers about the prospectus, information on the electronic application process, and details about the listing application and structure of the offering. There is no financial performance data, audit information, management discussion, or earnings results. The document is clearly an announcement about a capital raising event (IPO) and related offering details, not a report or transcript. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, supporting a high confidence in this classification.
2022-11-28 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.